Press Releases

Date Title and Summary Additional Formats
Toggle Summary Concert Pharmaceuticals Awarded $488,000 Therapeutic Discovery Project Grants
Grants Supports Development of Novel Deuterium-Modified Therapies
View HTML
Toggle Summary Concert Pharmaceuticals to Present at the Oppenheimer 21st Annual Healthcare Conference on November 3, 2010
Concert Pharmaceuticals to Present at the Oppenheimer 21st Annual Healthcare Conference on November 3, 2010 Lexington, MA –- Concert Pharmaceuticals, Inc. announced today that Roger Tung, Ph.D., President and Chief Executive Officer of Concert, will present at the Oppenheimer 21st Annual Healthcare
View HTML
Toggle Summary Concert Pharmaceuticals to Present at the Stifel Nicolaus Healthcare Conference on September 16, 2010
Concert Pharmaceuticals to Present at the Stifel Nicolaus Healthcare Conference on September 16, 2010 Lexington, MA –– Concert Pharmaceuticals, Inc. announced today that Roger Tung, Ph.D., President and Chief Executive Officer of Concert, will present at the 2010 Stifel Nicolaus Healthcare
View HTML
Toggle Summary Gregory Miller Joins Concert Pharmaceuticals as Head of Business and Corporate Development
Gregory Miller Joins Concert Pharmaceuticals as Head of Business and Corporate Development Lexington, MA –– Concert Pharmaceuticals, Inc. today announced that Gregory L. Miller has joined the company as its new Head of Business and Corporate Development.
View HTML
Toggle Summary Concert Pharmaceuticals to Present at Canaccord Genuity Global Growth Conference on August 10, 2010
Concert Pharmaceuticals to Present at Canaccord Genuity Global Growth Conference on August 10, 2010 Lexington, MA ––Concert Pharmaceuticals, Inc. announced today that Roger Tung, Ph.D., President and Chief Executive Officer of Concert, will present at the Canaccord Genuity Global Growth Conference
View HTML
Toggle Summary Concert Pharmaceuticals to Participate in Drug Discovery and Development Panel at 2010 BIO International Convention
Concert Pharmaceuticals to Participate in Drug Discovery and Development Panel at 2010 BIO International Convention Lexington, MA –– Concert Pharmaceuticals, Inc. announced today that the company will be participating at the 2010 BIO International Convention being held at McCormick Place in
View HTML
Toggle Summary Concert Pharmaceuticals Granted Patent for Deuterated Paroxetine Compounds, Including CTP-347
Concert Pharmaceuticals Granted Patent for Deuterated Paroxetine Compounds, Including CTP-347 Lexington, Mass -- Concert Pharmaceuticals, Inc. announced that the US Patent and Trademark Office has issued U.S. Patent No. 7,678,914.   This patent specifically claims deuterium analogs of paroxetine,
View HTML
Toggle Summary Concert Pharmaceuticals to Present at the 30th Annual Cowen and Company Health Care Conference on Monday, March 8
Concert Pharmaceuticals to Present at the 30th Annual Cowen and Company Health Care Conference on Monday, March 8 Lexington, Mass -- Concert Pharmaceuticals, Inc. announced today that it will be presenting at the Cowen and Company 30th Annual Health Care Conference, being held March 8-11, 2010 at
View HTML
Toggle Summary Concert Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference on Monday, January 11
Concert Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference on Monday, January 11 Lexington, MA -- Concert Pharmaceuticals, Inc. announced today that it will be presenting at the 28th Annual J.P. Morgan Healthcare Conference, being held at the Westin St.
View HTML
Toggle Summary Concert Pharmaceuticals Initiates Phase 1b Clinical Trial of CTP-518, Protease Inhibitor for Treatment of HIV
Concert Earns $12 Million Milestone from GlaxoSmithKline CTP-518 has Potential as Unboosted HIV Protease Inhibitor
View HTML